QUVIVIQ
Total Payments
$9.7M
Transactions
114,202
Doctors
41,399
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $905,179 | 20,639 | 11,768 |
| 2023 | $7.7M | 76,300 | 32,849 |
| 2022 | $1.1M | 17,263 | 13,576 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.4M | 1,717 | 35.4% |
| Unspecified | $3.1M | 254 | 31.9% |
| Food and Beverage | $2.5M | 110,358 | 25.3% |
| Travel and Lodging | $398,093 | 1,657 | 4.1% |
| Consulting Fee | $297,353 | 94 | 3.1% |
| Space rental or facility fees (teaching hospital only) | $16,250 | 5 | 0.2% |
| Grant | $5,000 | 1 | 0.1% |
| Education | $4,256 | 116 | 0.0% |
Payments by Type
General
$6.6M
113,948 transactions
Research
$3.1M
254 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, CROSSOVER PHASE 1 TRIAL TO INVESTIGATE BIOEQUIVALENCE BETWEEN 5 X 10 MG TABLETS AND 2 X 25 MG TABLETS OF DARIDOREXANT IN HEALTHY MALE AND FEMALE JAPANESE PARTICIPANTS | IDORSIA PHARMACEUTICALS US INC | $1.5M | 0 |
| MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, POLYSOMNOGRAPHY, DOSE-FINDING STUDY ASSESSING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MULTIPLE-DOSE ORAL ADMINISTRATION OF DARIDOREXANT IN PEDIATRIC SUBJECTS AGED 10 TO < 18 YEARS WITH INSOMNIA DISORDER | IDORSIA PHARMACEUTICALS US INC | $819,476 | 0 |
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 2-WAY CROSS-OVER POST APPROVAL STUDY TO INVESTIGATE THE EFFICACY OF DARIDOREXANT IN SUBJECTS WITH INSOMNIA AND COMORBID NOCTURIA | IDORSIA PHARMACEUTICALS US INC | $355,553 | 0 |
| A PROSPECTIVE, OPEN-LABEL, SINGLE-DOSE PHASE 1 STUDY TO MEASURE DARIDOREXANT IN BREAST MILK OF HEALTHY LACTATING WOMEN | IDORSIA PHARMACEUTICALS US INC | $241,560 | 0 |
| MULTI-CENTER DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED PARALLEL-GROUP POLYSOMNOGRAPHY DOSE-FINDING STUDY ASSESSING THE EFFICACY SAFETY AND PHARMACOKINETICS OF MULTIPLE-DOSE ORAL ADMINISTRATION OF DARIDOREXANT IN PEDIATRIC SUBJECTS AGED 10 TO < 18 YEARS WITH INSOMNIA DISORDER | IDORSIA PHARMACEUTICALS US INC | $148,130 | 0 |
| CLINCIAL PRACTICE GUIDELINES ON SWITCHING HYPNOTIC MEDICINES (CONSENSUS; PUBLICATION) | IDORSIA PHARMACEUTICALS US INC | $50,363 | 5 |
| RETROSPECTIVE OBSERVATIONAL ANALYSIS (PUBLICATION) | IDORSIA PHARMACEUTICALS US INC | $16,170 | 2 |
Top Doctors Receiving Payments for QUVIVIQ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $3.1M | 263 |
| , M.D | Sleep Medicine | Wilson, NC | $126,007 | 162 |
| , MD | Pulmonary Disease | Cincinnati, OH | $123,001 | 111 |
| , MD | Psychiatry | Hallandale Beach, FL | $122,356 | 262 |
| , MD | Sleep Medicine | Los Angeles, CA | $107,183 | 118 |
| , M.D | Pulmonary Disease | Abington, PA | $106,418 | 103 |
| , M.D | Psychiatry | Bellevue, WA | $91,872 | 144 |
| , MD | Internal Medicine | Pacific Palisades, CA | $85,149 | 186 |
| , MD, MPH | Psychiatry | Pomona, NY | $81,690 | 74 |
| , MD | Sleep Medicine | Daphne, AL | $75,470 | 84 |
| , MD | Neurology | Seattle, WA | $72,359 | 27 |
| , M.D | Family Medicine | Lake Charles, LA | $69,959 | 67 |
| Jeffrey Richmond | Psychiatry | Denver, CO | $69,055 | 117 |
| , M.D | Pulmonary Disease | Columbia, SC | $68,258 | 49 |
| , MD | Sleep Medicine | Frisco, TX | $67,502 | 67 |
| Michael Saribalas | Psychiatry | Columbus, OH | $66,594 | 54 |
| , M.D | Psychiatry | Murrieta, CA | $65,867 | 121 |
| , MD | Sleep Medicine | Greenwood, IN | $64,929 | 76 |
| , M.D | Sleep Medicine | Williamsville, NY | $61,657 | 74 |
| , MD | Family Medicine | Collegeville, PA | $53,784 | 64 |
| , M.D | Sleep Medicine | Little Rock, AR | $51,102 | 41 |
| , M.D | Neurology | Savannah, GA | $48,877 | 63 |
| , M.D | Family Medicine | Bradenton, FL | $47,904 | 72 |
| , M.B.B.S | Psychiatry | Omaha, NE | $47,594 | 61 |
| , M.D | Physical Medicine & Rehabilitation | Bethesda, MD | $47,185 | 50 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $9.7M
- Total Doctors 41,399
- Transactions 114,202
About QUVIVIQ
QUVIVIQ is a drug associated with $9.7M in payments to 41,399 healthcare providers, recorded across 114,202 transactions in the CMS Open Payments database. The primary manufacturer is IDORSIA PHARMACEUTICALS US INC.
Payment data is available from 2022 to 2024. In 2024, $905,179 was paid across 20,639 transactions to 11,768 doctors.
The most common payment nature for QUVIVIQ is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.4M, 35.4% of total).
QUVIVIQ is associated with 7 research studies, including "A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, CROSSOVER PHASE 1 TRIAL TO INVESTIGATE BIOEQUIVALENCE BETWEEN 5 X 10 MG TABLETS AND 2 X 25 MG TABLETS OF DARIDOREXANT IN HEALTHY MALE AND FEMALE JAPANESE PARTICIPANTS" ($1.5M).